{"protocolSection":{"identificationModule":{"nctId":"NCT02839746","orgStudyIdInfo":{"id":"1160.253"},"organization":{"fullName":"Boehringer Ingelheim","class":"INDUSTRY"},"briefTitle":"Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)","officialTitle":"Non-interventional Study Describing Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)"},"statusModule":{"statusVerifiedDate":"2019-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-06-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-10-10","type":"ACTUAL"},"completionDateStruct":{"date":"2018-10-10","type":"ACTUAL"},"studyFirstSubmitDate":"2016-06-02","studyFirstSubmitQcDate":"2016-07-18","studyFirstPostDateStruct":{"date":"2016-07-21","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-10-10","resultsFirstSubmitQcDate":"2019-10-10","resultsFirstPostDateStruct":{"date":"2019-11-01","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-10-10","lastUpdatePostDateStruct":{"date":"2019-11-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Boehringer Ingelheim","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"Describe patient and physician assessed factors for patient well-being when treated with Pradaxa for stroke and embolism prevention in atrial fibrillation either compared to previous antithrombotic treatment (switcher)"},"conditionsModule":{"conditions":["Atrial Fibrillation"]},"designModule":{"studyType":"OBSERVATIONAL","designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":671,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Dabigatran","description":"Patients switched from vitamin K antagonist (VKA) to dabigatran"}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Mean of Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores at Second Assessment Compared to Baseline Assessment","description":"The PACT-Q is self-administered quest. which was developed as means to investigate patients' satisfaction with anticoagulant treatment \\& treatment convenience in patients with deep venous thrombosis (DVT), pulmonary embolism (PE) or atrial fibrillation (AF). PACT-Q2 quest. is made up of two domains: (1) Convenience (13 items): This domain is calculated by adding inverted scores (6-item score) for each of the 13 items in question \\& converting to a scale from 0 to 100. (2) Satisfaction with the anticoagulant treatment (7 items): This domain is calculated by adding scores for each of the 7 items in question \\& converting to a scale from 0 to 100. The missing items have been replaced by the mean of non-missing items of the dimension (if 50% of items were completed, non-missing), in order to calculate domains score. The higher the score, the higher the convenience/satisfaction. The two domain scores are presented for Baseline, Visit 2 (second assessment) as mean \\& standard deviation (SD).","timeFrame":"When planned to be switched from VKA to Pradaxa® (At baseline, Visit 1), 7 to 124 days after starting treatment with Pradaxa® (initiation period, Visit 2)"},{"measure":"Mean of Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores at Last Assessment Compared to Baseline Assessment","description":"The PACT-Q is self-administered quest. which was developed as means to investigate patients satisfaction with anticoagulant treatment \\& treatment convenience in patients with deep venous thrombosis (DVT), pulmonary embolism (PE) or atrial fibrillation (AF). The PACT-Q2 quest. is made up of two domains: 1) Convenience (13 items): This domain is calculated by adding inverted scores (6-item score) for each of the 13 items in question, \\&converting to a scale from 0 to 100. 2) Satisfaction with the anticoagulant treatment (7 items):This domain is calculated by adding scores for each of the 7 items in question, \\& converting to a scale from 0 to 100.\n\nThe missing items have been replaced by the mean of non-missing items of the dimension (if 50% of items were completed, non-missing), in order to calculate domains score. The higher the score, the higher the convenience/satisfaction.\n\nThe two domain scores are presented for Baseline, Visit 3 (last assessment) as mean and standard deviation (SD).","timeFrame":"When planned to be switched from VKA to Pradaxa® (At baseline, Visit 1), 125 to 365 days after starting treatment with Pradaxa® (continuation period, Visit 3)"},{"measure":"Mean of Perception of Anticoagulant Treatment Questionnaire (PACT-Q2) Score at Last Assessment Compared to Second Assessment","description":"The PACT-Q is self-administered quest. which was developed as means to investigate patients satisfaction with anticoagulant treatment \\& treatment convenience in patients with DVT, PE or AF. The PACT-Q2 quest. is made up of two domains: 1) Convenience (13 items): This domain is calculated by adding inverted scores (6-item score) for each of the 13 items in question, \\&converting to a scale from 0 to 100. 2) Satisfaction with the anticoagulant treatment (7 items):This domain is calculated by adding scores for each of the 7 items in question, \\& converting to a scale from 0 to 100. The missing items have been replaced by the mean of non-missing items of dimension (if 50% of items were completed, non-missing), in order to calculate domains score. The higher the score, the higher the convenience/satisfaction.\n\nThe two domain scores are presented for Visit 2( second assessment), Visit 3 (last assessment) as mean and standard deviation (SD).","timeFrame":"7 to 124 days after starting treatment with Pradaxa® (initiation period, Visit 2), 125 to 365 days after starting treatment with Pradaxa® (continuation period, Visit 3)"}],"secondaryOutcomes":[{"measure":"Patient Characteristics at Baseline - CHA2DS2-VASc Stroke Risk Score and HAS-BLED Bleeding Risk Score","description":"CHA2DS2-VASc stroke risk score is calculated based on following conditions: Congestive heart failure/left ventricular dysfunction, Hypertension, Age (≥ 75), Diabetes Mellitus,Stroke/Transient Ischaemic Attack (TIA)/thromboembolism,Vascular disease (history of myocardial infarction, peripheral artery disease or aortic plaque) ,Age 65-74, Sex category. HAS-BLED bleeding risk score is calculated based on following conditions: Uncontrolled hypertension with Systolic Blood pressure (SBP) ≥ 160 mmHg,Kidney failure,liver failure,History of stroke,History of bleeding, anaemia or predisposition to bleeding,Unstable/high or poor international normalized ratio (INR) (\\<60% of time within therapeutic range),Elderly (\\>65 years),Medications that affect haemostasis,Consumptions of ≥8 alcoholic drinks per week.CHA2DS2-VASc stroke risk score \\& HAS-BLED bleeding risk score range from 0 to 9 with 0 being outcome with low stroke risk for CHA2DS2-VASc and being with low bleeding risk for HAS-BLED.","timeFrame":"Baseline"},{"measure":"Patient Characteristics at Baseline - Categorical Parameters","description":"Categorical parameters of the patient characteristics at baseline included age, Risk factors associated with stroke and/or haemorrhage in the medical history (MH), co-morbidities (CoMo), concomitant medication (CM) and dosing of Pradaxa® (DoP).\n\nHaemorrhagic risk (HAS-BLED) is categorized as Low risk (score 0), Moderate risk (score 1-2) and High Risk (score ≥3). Thromboembolic risk (CHA2DS2-VASc) is categorized as Low risk (score 0 in male and 1 in female), Moderate risk (score 1 in male and 2 in female) and High Risk (score ≥2 in male and ≥3 in female).\n\nStages of kidney disease are categorized based on Cockcroft-Gault review as below:\n\nNo kidney failure (\\> 80 ml/min), Mild kidney failure (50-80 ml/min), Moderate kidney failure (30-49 ml/min), Severe kidney failure (15-29 ml/min) and End-stage kidney failure/dialysis (\\< 15 ml/min).","timeFrame":"Baseline"},{"measure":"Patient Characteristics at Baseline - Creatinine Clearance","description":"Creatinine clearance at baseline is a measure of the patient's kidney function and is one of the baseline patient characteristics.","timeFrame":"Baseline"},{"measure":"Patient Characteristics at Baseline - Vitamin K Antagonist Treatment Duration","description":"Vitamin K Antagonist (VKA) treatment duration is one of the baseline patient characteristics.","timeFrame":"Baseline"},{"measure":"Patient Characteristics at Baseline - Reasons for Switching From VKAs to Pradaxa®","description":"Categories of reasons for switching from VKAs to Pradaxa® are as below:\n\n1. Hypersensitivity (Hypersensitivity to the drug)\n2. Intracranial haemorrhage (Patients with a history of intracranial haemorrhage (ICH) (except during the acute phase) in whom the benefits of anticoagulation were deemed to outweigh the risk of haemorrhage)\n3. Ischaemic stroke (Patients with ischaemic stroke who present clinical and neuroimaging criteria indicating a high risk of ICH)\n4. Arterial thromboembolic episodes (Patients undergoing treatment with VKAs, suffering from severe arterial thromboembolic episodes despite good INR control)\n5. INR not in range (Patients who have started treatment with VKAs in whom it is not possible to keep the INR in range (2-3) despite good therapeutic compliance)\n6. INR management (Lack of access to conventional INR management)\n7. Pts decision (Patient's decision)\n8. Others.\n\nA single patient may have specified more than one reason","timeFrame":"Baseline"},{"measure":"Reason for Changing the Dose of Pradaxa®: 150 mg/ Twice Daily (Bid) to 110 mg/Bid","description":"Reasons for for changing the dose of Pradaxa®: 150 mg/bid to 110 mg/bid are categorized as below:\n\n1\\] High risk of bleeding 2\\] Moderate renal failure 3\\] \\>80 years 4\\] Other reason","timeFrame":"7 to 124 days after starting treatment with Pradaxa® (initiation period, Visit 2), 125 to 365 days after starting treatment with Pradaxa® (continuation period, Visit 3)"},{"measure":"Reason for Changing the Dose of Pradaxa®: 110 mg/Bid to 150 mg/Bid","description":"Reasons for for changing the dose of Pradaxa®: 110 mg/bid to 150 mg/bid are categorized as below:\n\n1\\] High risk of bleeding 2\\] Moderate renal failure 3\\] \\>80 years 4\\] Other reason","timeFrame":"7 to 124 days after starting treatment with Pradaxa® (initiation period, Visit 2), 125 to 365 days after starting treatment with Pradaxa® (continuation period, Visit 3)"},{"measure":"Reasons for no Longer Receiving Pradaxa® Treatment","description":"Reasons for no longer receiving Pradaxa® treatment categorized as below:\n\n1. Treatment change (Change of treatment (by patient or by investigator)\n2. Adverse event (Diarrhea, gastrointestinal discomfort, rectorrhagia, dyspepsia)\n3. Exitus\n4. Others","timeFrame":"7 to 124 days after starting treatment with Pradaxa® (initiation period, Visit 2), 125 to 365 days after starting treatment with Pradaxa® (continuation period, Visit 3)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Written informed consent prior to participation\n* Female and male patients 18 years of age or older with a diagnosis of non-valvular atrial fibrillation.\n* At least 6 months of continuous vitamin K antagonist (VKA) treatment for stroke prevention prior to baseline assessment.\n* Patients switched to Pradaxa® according to Summary of Product Characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community.\n\nExclusion criteria:\n\n* Contraindication to the use of Pradaxa® or VKA as described in the Summary of Product Characteristics (SmPC)\n* Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in non-valvular atrial fibrillation.\n* Current participation in any clinical trial of a drug or device","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"spanish patients with a diagnosis of non-valvular atrial fibrillation","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Boehringer Ingelheim","affiliation":"Boehringer Ingelheim","role":"STUDY_CHAIR"}],"locations":[{"city":"Multiple Locations","country":"Spain"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"All participants were screened for eligibility to participate in the study. Participants attended specialist sites which would then ensure that all participants met all inclusion/exclusion criteria. Participants were not to be entered if any one of the specific entry criteria were not met.","recruitmentDetails":"The data collection periods:\n\n* When planned to be switched from vitamin K antagonists (VKA) to Pradaxa® (At baseline, Visit 1)\n* 7 to 124 days after starting treatment with Pradaxa® (initiation period, Visit 2)\n* 125 to 365 days after starting treatment with Pradaxa® (continuation period, Visit 3)\n\nQuestionnaire (quest.)","groups":[{"id":"FG000","title":"Dabigatran Etexilate (Pradaxa®)","description":"Patients with Non-valvular atrial fibrillation (NVAF) who were treated with vitamin K antagonists (VKAs) and subsequently started daily oral dose of Pradaxa® 110 milligram (mg) or 150 mg hard capsules containing dabigatran etexilate according to the Summary of Product characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"671"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"659"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"12"}]}],"dropWithdraws":[{"type":"Not met selection criteria","reasons":[{"groupId":"FG000","numSubjects":"12"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Eligible patients: All patients (pts) fulfilling all inclusion criteria and no exclusion criteria.","groups":[{"id":"BG000","title":"Total","description":"Patients with Non-valvular atrial fibrillation (NVAF) who were treated with vitamin K antagonists (VKAs) and subsequently started daily dose of Pradaxa® 110 mg or 150 mg hard capsules containing dabigatran etexilate according to the Summary of Product characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"659"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"73.12","spread":"9.39"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"275"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"384"}]}]}]},{"title":"Race/Ethnicity, Customized","description":"Race information is provided. Ethnicity information was not collected for this study.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"638"}]}]},{"title":"North African","categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]},{"title":"Latin American","categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Mean of Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores at Second Assessment Compared to Baseline Assessment","description":"The PACT-Q is self-administered quest. which was developed as means to investigate patients' satisfaction with anticoagulant treatment \\& treatment convenience in patients with deep venous thrombosis (DVT), pulmonary embolism (PE) or atrial fibrillation (AF). PACT-Q2 quest. is made up of two domains: (1) Convenience (13 items): This domain is calculated by adding inverted scores (6-item score) for each of the 13 items in question \\& converting to a scale from 0 to 100. (2) Satisfaction with the anticoagulant treatment (7 items): This domain is calculated by adding scores for each of the 7 items in question \\& converting to a scale from 0 to 100. The missing items have been replaced by the mean of non-missing items of the dimension (if 50% of items were completed, non-missing), in order to calculate domains score. The higher the score, the higher the convenience/satisfaction. The two domain scores are presented for Baseline, Visit 2 (second assessment) as mean \\& standard deviation (SD).","populationDescription":"Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria. The analyses were performed based on actual anticoagulant treatment (AT) received by pts (i.e. \"as-treated\" analysis),so that pts who discontinued the initial AT during time of an assessment were excluded from all analyses where data from that assessment was included","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units on Scale","timeFrame":"When planned to be switched from VKA to Pradaxa® (At baseline, Visit 1), 7 to 124 days after starting treatment with Pradaxa® (initiation period, Visit 2)","groups":[{"id":"OG000","title":"Dabigatran Etexilate (Pradaxa®)","description":"Patients with Non-valvular atrial fibrillation (NVAF) who were treated with vitamin K antagonists (VKAs) and subsequently started daily oral dose of Pradaxa® 110 milligram (mg) or 150 mg hard capsules containing dabigatran etexilate according to the Summary of Product characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"classes":[{"title":"Convenience-Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"512"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"59.86","spread":"25.39"}]}]},{"title":"Convenience-Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"512"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80.96","spread":"16.98"}]}]},{"title":"Satisfaction-Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"511"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49.15","spread":"17.88"}]}]},{"title":"Satisfaction-Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"511"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.35","spread":"14.26"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Within group comparison of Baseline convenience with that of Visit 2.","nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"non-parametric Wilcoxon signed-rank"},{"groupIds":["OG000"],"groupDescription":"Within group comparison of Baseline satisfaction with that of Visit 2.","nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"non-parametric Wilcoxon signed-rank"}]},{"type":"PRIMARY","title":"Mean of Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores at Last Assessment Compared to Baseline Assessment","description":"The PACT-Q is self-administered quest. which was developed as means to investigate patients satisfaction with anticoagulant treatment \\& treatment convenience in patients with deep venous thrombosis (DVT), pulmonary embolism (PE) or atrial fibrillation (AF). The PACT-Q2 quest. is made up of two domains: 1) Convenience (13 items): This domain is calculated by adding inverted scores (6-item score) for each of the 13 items in question, \\&converting to a scale from 0 to 100. 2) Satisfaction with the anticoagulant treatment (7 items):This domain is calculated by adding scores for each of the 7 items in question, \\& converting to a scale from 0 to 100.\n\nThe missing items have been replaced by the mean of non-missing items of the dimension (if 50% of items were completed, non-missing), in order to calculate domains score. The higher the score, the higher the convenience/satisfaction.\n\nThe two domain scores are presented for Baseline, Visit 3 (last assessment) as mean and standard deviation (SD).","populationDescription":"Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.The analyses were performed based on actual anticoagulant treatment (AT) received by pts (i.e. \"as-treated\" analysis),so that pts who discontinued the initial AT during time of an assessment were excluded from all analyses where data from that assessment was included","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units on Scale","timeFrame":"When planned to be switched from VKA to Pradaxa® (At baseline, Visit 1), 125 to 365 days after starting treatment with Pradaxa® (continuation period, Visit 3)","groups":[{"id":"OG000","title":"Dabigatran Etexilate (Pradaxa®)","description":"Patients with Non-valvular atrial fibrillation (NVAF) who were treated with vitamin K antagonists (VKAs) and subsequently started daily oral dose of Pradaxa® 110 milligram (mg) or 150 mg hard capsules containing dabigatran etexilate according to the Summary of Product characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"classes":[{"title":"Convenience-Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"491"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.19","spread":"25.59"}]}]},{"title":"Convenience-Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"491"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.29","spread":"15.19"}]}]},{"title":"Satisfaction-Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49.44","spread":"17.74"}]}]},{"title":"Satisfaction-Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.19","spread":"14.80"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Within group comparison of Baseline convenience with that of Visit 3.","nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"non-parametric Wilcoxon signed-rank"},{"groupIds":["OG000"],"nonInferiorityType":"OTHER","nonInferiorityComment":"Within group comparison of Baseline satisfaction with that of Visit 3.","pValue":"<0.0001","statisticalMethod":"non-parametric Wilcoxon signed-rank]"}]},{"type":"PRIMARY","title":"Mean of Perception of Anticoagulant Treatment Questionnaire (PACT-Q2) Score at Last Assessment Compared to Second Assessment","description":"The PACT-Q is self-administered quest. which was developed as means to investigate patients satisfaction with anticoagulant treatment \\& treatment convenience in patients with DVT, PE or AF. The PACT-Q2 quest. is made up of two domains: 1) Convenience (13 items): This domain is calculated by adding inverted scores (6-item score) for each of the 13 items in question, \\&converting to a scale from 0 to 100. 2) Satisfaction with the anticoagulant treatment (7 items):This domain is calculated by adding scores for each of the 7 items in question, \\& converting to a scale from 0 to 100. The missing items have been replaced by the mean of non-missing items of dimension (if 50% of items were completed, non-missing), in order to calculate domains score. The higher the score, the higher the convenience/satisfaction.\n\nThe two domain scores are presented for Visit 2( second assessment), Visit 3 (last assessment) as mean and standard deviation (SD).","populationDescription":"Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria. The analyses were performed based on actual anticoagulant treatment (AT) received by pts (i.e. \"as-treated\" analysis),so that pts who discontinued the initial AT during time of an assessment were excluded from all analyses where data from that assessment was included","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"unit on scale","timeFrame":"7 to 124 days after starting treatment with Pradaxa® (initiation period, Visit 2), 125 to 365 days after starting treatment with Pradaxa® (continuation period, Visit 3)","groups":[{"id":"OG000","title":"Dabigatran Etexilate (Pradaxa®)","description":"Patients with Non-valvular atrial fibrillation (NVAF) who were treated with vitamin K antagonists (VKAs) and subsequently started daily oral dose of Pradaxa® 110 milligram (mg) or 150 mg hard capsules containing dabigatran etexilate according to the Summary of Product characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"classes":[{"title":"Convenience-Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"486"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80.95","spread":"17.01"}]}]},{"title":"Convenience-Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"486"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.23","spread":"15.24"}]}]},{"title":"Satisfaction-Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"483"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.54","spread":"14.22"}]}]},{"title":"Satisfaction-Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"483"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.30","spread":"14.66"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Within group comparison of visit 2 convenience with that of Visit 3.","nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"non-parametric Wilcoxon signed-rank"},{"groupIds":["OG000"],"groupDescription":"Within group comparison of visit 2 satisfaction with that of Visit 3.","nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"non-parametric Wilcoxon signed-rank"}]},{"type":"SECONDARY","title":"Patient Characteristics at Baseline - CHA2DS2-VASc Stroke Risk Score and HAS-BLED Bleeding Risk Score","description":"CHA2DS2-VASc stroke risk score is calculated based on following conditions: Congestive heart failure/left ventricular dysfunction, Hypertension, Age (≥ 75), Diabetes Mellitus,Stroke/Transient Ischaemic Attack (TIA)/thromboembolism,Vascular disease (history of myocardial infarction, peripheral artery disease or aortic plaque) ,Age 65-74, Sex category. HAS-BLED bleeding risk score is calculated based on following conditions: Uncontrolled hypertension with Systolic Blood pressure (SBP) ≥ 160 mmHg,Kidney failure,liver failure,History of stroke,History of bleeding, anaemia or predisposition to bleeding,Unstable/high or poor international normalized ratio (INR) (\\<60% of time within therapeutic range),Elderly (\\>65 years),Medications that affect haemostasis,Consumptions of ≥8 alcoholic drinks per week.CHA2DS2-VASc stroke risk score \\& HAS-BLED bleeding risk score range from 0 to 9 with 0 being outcome with low stroke risk for CHA2DS2-VASc and being with low bleeding risk for HAS-BLED.","populationDescription":"Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"unit on scale","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Dabigatran Etexilate (Pradaxa®)","description":"Patients with Non-valvular atrial fibrillation (NVAF) who were treated with vitamin K antagonists (VKAs) and subsequently started daily oral dose of Pradaxa® 110 milligram (mg) or 150 mg hard capsules containing dabigatran etexilate according to the Summary of Product characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"classes":[{"title":"CHA2DS2-VASc","categories":[{"measurements":[{"groupId":"OG000","value":"3.60","spread":"1.56"}]}]},{"title":"HAS-BLED","categories":[{"measurements":[{"groupId":"OG000","value":"2.10","spread":"0.98"}]}]}]},{"type":"SECONDARY","title":"Patient Characteristics at Baseline - Categorical Parameters","description":"Categorical parameters of the patient characteristics at baseline included age, Risk factors associated with stroke and/or haemorrhage in the medical history (MH), co-morbidities (CoMo), concomitant medication (CM) and dosing of Pradaxa® (DoP).\n\nHaemorrhagic risk (HAS-BLED) is categorized as Low risk (score 0), Moderate risk (score 1-2) and High Risk (score ≥3). Thromboembolic risk (CHA2DS2-VASc) is categorized as Low risk (score 0 in male and 1 in female), Moderate risk (score 1 in male and 2 in female) and High Risk (score ≥2 in male and ≥3 in female).\n\nStages of kidney disease are categorized based on Cockcroft-Gault review as below:\n\nNo kidney failure (\\> 80 ml/min), Mild kidney failure (50-80 ml/min), Moderate kidney failure (30-49 ml/min), Severe kidney failure (15-29 ml/min) and End-stage kidney failure/dialysis (\\< 15 ml/min).","populationDescription":"Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Dabigatran Etexilate (Pradaxa®)","description":"Patients with Non-valvular atrial fibrillation (NVAF) who were treated with vitamin K antagonists (VKAs) and subsequently started daily oral dose of Pradaxa® 110 milligram (mg) or 150 mg hard capsules containing dabigatran etexilate according to the Summary of Product characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"classes":[{"title":"Age: ≤65 years","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"132"}]}]},{"title":"Age: >65 years","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"527"}]}]},{"title":"MH: Ischaemic stroke","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88"}]}]},{"title":"MH: Thromboembolisms","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]},{"title":"MH: Diabetes mellitus","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"159"}]}]},{"title":"MH: Arterial hypertension","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"351"}]}]},{"title":"MH: Ischemic heart disease or Heart failure","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"136"}]}]},{"title":"MH: Peripheral arterial disease","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}]},{"title":"MH: Kidney failure","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]},{"title":"MH: Liver failure","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"CoMo: Yes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"425"}]}]},{"title":"CoMo: No","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"231"}]}]},{"title":"CoMo: Not assessed","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"CM: Yes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"597"}]}]},{"title":"CM: No","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62"}]}]},{"title":"DoP: 110 mg twice daily","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"244"}]}]},{"title":"DoP: 150 mg twice daily","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"415"}]}]},{"title":"HAS-BLED: Low","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}]},{"title":"HAS-BLED: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"435"}]}]},{"title":"HAS-BLED: High","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"201"}]}]},{"title":"CHA2DS2-VASc: Low","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"CHA2DS2-VASc: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60"}]}]},{"title":"CHA2DS2-VASc: High","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"591"}]}]},{"title":"No kidney failure","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"643"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"211"}]}]},{"title":"Mild kidney failure","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"643"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"385"}]}]},{"title":"Moderate kidney failure","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"643"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44"}]}]},{"title":"Severe kidney failure","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"643"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"End-stage kidney failure/dialysis","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"643"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Patient Characteristics at Baseline - Creatinine Clearance","description":"Creatinine clearance at baseline is a measure of the patient's kidney function and is one of the baseline patient characteristics.","populationDescription":"Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"millilitre/ minute [mL/min]","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Dabigatran Etexilate (Pradaxa®)","description":"Patients with Non-valvular atrial fibrillation (NVAF) who were treated with vitamin K antagonists (VKAs) and subsequently started daily oral dose of Pradaxa® 110 milligram (mg) or 150 mg hard capsules containing dabigatran etexilate according to the Summary of Product characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.91","spread":"22.72"}]}]}]},{"type":"SECONDARY","title":"Patient Characteristics at Baseline - Vitamin K Antagonist Treatment Duration","description":"Vitamin K Antagonist (VKA) treatment duration is one of the baseline patient characteristics.","populationDescription":"Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Months","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Dabigatran Etexilate (Pradaxa®)","description":"Patients with Non-valvular atrial fibrillation (NVAF) who were treated with vitamin K antagonists (VKAs) and subsequently started daily oral dose of Pradaxa® 110 milligram (mg) or 150 mg hard capsules containing dabigatran etexilate according to the Summary of Product characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.83","spread":"46.51"}]}]}]},{"type":"SECONDARY","title":"Patient Characteristics at Baseline - Reasons for Switching From VKAs to Pradaxa®","description":"Categories of reasons for switching from VKAs to Pradaxa® are as below:\n\n1. Hypersensitivity (Hypersensitivity to the drug)\n2. Intracranial haemorrhage (Patients with a history of intracranial haemorrhage (ICH) (except during the acute phase) in whom the benefits of anticoagulation were deemed to outweigh the risk of haemorrhage)\n3. Ischaemic stroke (Patients with ischaemic stroke who present clinical and neuroimaging criteria indicating a high risk of ICH)\n4. Arterial thromboembolic episodes (Patients undergoing treatment with VKAs, suffering from severe arterial thromboembolic episodes despite good INR control)\n5. INR not in range (Patients who have started treatment with VKAs in whom it is not possible to keep the INR in range (2-3) despite good therapeutic compliance)\n6. INR management (Lack of access to conventional INR management)\n7. Pts decision (Patient's decision)\n8. Others.\n\nA single patient may have specified more than one reason","populationDescription":"Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Dabigatran Etexilate (Pradaxa®)","description":"Patients with Non-valvular atrial fibrillation (NVAF) who were treated with vitamin K antagonists (VKAs) and subsequently started daily oral dose of Pradaxa® 110 milligram (mg) or 150 mg hard capsules containing dabigatran etexilate according to the Summary of Product characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"classes":[{"title":"Hypersenstitivity","categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]},{"title":"Intracranial haemorrhage","categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]},{"title":"Ischaemic stroke","categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]},{"title":"Arterial thromboembolic episodes","categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}]},{"title":"INR not in range","categories":[{"measurements":[{"groupId":"OG000","value":"484"}]}]},{"title":"INR management","categories":[{"measurements":[{"groupId":"OG000","value":"45"}]}]},{"title":"Pts decision","categories":[{"measurements":[{"groupId":"OG000","value":"137"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]}]},{"type":"SECONDARY","title":"Reason for Changing the Dose of Pradaxa®: 150 mg/ Twice Daily (Bid) to 110 mg/Bid","description":"Reasons for for changing the dose of Pradaxa®: 150 mg/bid to 110 mg/bid are categorized as below:\n\n1\\] High risk of bleeding 2\\] Moderate renal failure 3\\] \\>80 years 4\\] Other reason","populationDescription":"Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 to 124 days after starting treatment with Pradaxa® (initiation period, Visit 2), 125 to 365 days after starting treatment with Pradaxa® (continuation period, Visit 3)","groups":[{"id":"OG000","title":"Dabigatran Etexilate (Pradaxa®)","description":"Patients with Non-valvular atrial fibrillation (NVAF) who were treated with vitamin K antagonists (VKAs) and subsequently started daily oral dose of Pradaxa® 110 milligram (mg) or 150 mg hard capsules containing dabigatran etexilate according to the Summary of Product characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"classes":[{"title":"High risk of bleeding- Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"620"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Moderate renal failure- Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"620"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":">80 years- Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"620"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Other reason- Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"620"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"High risk of bleeding- Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"586"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate renal failure- Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"586"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":">80 years- Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"586"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Other reason- Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"586"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}]},{"type":"SECONDARY","title":"Reason for Changing the Dose of Pradaxa®: 110 mg/Bid to 150 mg/Bid","description":"Reasons for for changing the dose of Pradaxa®: 110 mg/bid to 150 mg/bid are categorized as below:\n\n1\\] High risk of bleeding 2\\] Moderate renal failure 3\\] \\>80 years 4\\] Other reason","populationDescription":"Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 to 124 days after starting treatment with Pradaxa® (initiation period, Visit 2), 125 to 365 days after starting treatment with Pradaxa® (continuation period, Visit 3)","groups":[{"id":"OG000","title":"Dabigatran Etexilate (Pradaxa®)","description":"Patients with Non-valvular atrial fibrillation (NVAF) who were treated with vitamin K antagonists (VKAs) and subsequently started daily oral dose of Pradaxa® 110 milligram (mg) or 150 mg hard capsules containing dabigatran etexilate according to the Summary of Product characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"classes":[{"title":"High risk of bleeding- Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"620"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate renal failure- Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"620"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":">80 years- Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"620"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Other reason- Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"620"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"High risk of bleeding- Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"586"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate renal failure- Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"586"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":">80 years- Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"586"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Other reason- Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"586"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}]},{"type":"SECONDARY","title":"Reasons for no Longer Receiving Pradaxa® Treatment","description":"Reasons for no longer receiving Pradaxa® treatment categorized as below:\n\n1. Treatment change (Change of treatment (by patient or by investigator)\n2. Adverse event (Diarrhea, gastrointestinal discomfort, rectorrhagia, dyspepsia)\n3. Exitus\n4. Others","populationDescription":"Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 to 124 days after starting treatment with Pradaxa® (initiation period, Visit 2), 125 to 365 days after starting treatment with Pradaxa® (continuation period, Visit 3)","groups":[{"id":"OG000","title":"Dabigatran Etexilate (Pradaxa®)","description":"Patients with Non-valvular atrial fibrillation (NVAF) who were treated with vitamin K antagonists (VKAs) and subsequently started daily oral dose of Pradaxa® 110 milligram (mg) or 150 mg hard capsules containing dabigatran etexilate according to the Summary of Product characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"659"}]}],"classes":[{"title":"Treatment change- Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Adverse event- Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]},{"title":"Exitus- Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Other reason- Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"Treatment change- Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"Adverse event-- Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"Exitus- Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]},{"title":"Other reason- Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From signing the informed consent till end of the study; up to 365 days","eventGroups":[{"id":"EG000","title":"Dabigatran Etexilate (Pradaxa®)","description":"Patients with Non-valvular atrial fibrillation (NVAF) who were treated with vitamin K antagonists (VKAs) and subsequently started daily oral dose of Pradaxa® 110 milligram (mg) or 150 mg hard capsules containing dabigatran etexilate according to the Summary of Product characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community.","deathsNumAffected":8,"deathsNumAtRisk":653,"seriousNumAffected":14,"seriousNumAtRisk":653,"otherNumAffected":0,"otherNumAtRisk":653}],"seriousEvents":[{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v20.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":653}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v20.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":653}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v20.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":653}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v20.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":653}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v20.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":653}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v20.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":653}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v20.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":653}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v20.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":653}]},{"term":"Joint injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v20.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":653}]},{"term":"Lower limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v20.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":653}]},{"term":"Brain neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v20.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":653}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v20.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":653}]},{"term":"Pancreatic carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v20.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":653}]},{"term":"Chronic kidney disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v20.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":653}]},{"term":"Cardiac pacemaker insertion","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA v20.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":653}]},{"term":"Waldenstrom's macroglobulinaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v20.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":653}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights."},"pointOfContact":{"title":"Boehringer Ingelheim, Call Center","organization":"Boehringer Ingelheim","email":"clintriage.rdg@boehringer-ingelheim.com","phone":"1-800-243-0127"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2015-11-30","uploadDate":"2019-09-30T09:32","filename":"Prot_000.pdf","size":857341},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-11-29","uploadDate":"2019-09-30T09:32","filename":"SAP_001.pdf","size":860354}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["Korea, Republic of"]},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M17245","name":"Vitamin K","relevance":"LOW"},{"id":"M17248","name":"Vitamins","relevance":"LOW"},{"id":"M490","name":"Dabigatran","relevance":"LOW"},{"id":"T481","name":"Vitamin K","relevance":"LOW"},{"id":"T450","name":"Menaquinone","relevance":"LOW"},{"id":"T449","name":"Menadione","relevance":"LOW"},{"id":"T452","name":"Naphthoquinone","relevance":"LOW"},{"id":"T458","name":"Phylloquinone","relevance":"LOW"}],"browseBranches":[{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Vi","name":"Vitamins"}]}},"hasResults":true}